Gammon M C, Banas M H, Boccumini L E, Sigal N H, Zweerink H J
Department of Immunology Research, Merck Sharp and Dohme Research Laboratories, Rahway, NJ 07065.
Cytotechnology. 1990 Jan;3(1):51-60. doi: 10.1007/BF00365266.
Fusion of lymphoblastoid cell lines that produce human monoclonal antibodies against Pseudomonas aeruginosa with the human/mouse heteromyeloma SHM-D33 generated heterohybrids that were stable and secreted antibody in the range of 20 to 300 micrograms/ml. One of the hybridoma cell lines ws adapted to serum-free medium and maintained for 60 days in an automated hollow fiber system. During that time, 3 g of antibody was produced. Such yields make it possible to evaluate these monoclonals for their therapeutic potential in patients at risk for Pseudomonas infections.